SAN
DIEGO, Nov. 26, 2024 /PRNewswire/ -- Regulus
Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company
focused on the discovery and development of innovative medicines
targeting microRNAs (the "Company" or "Regulus"), today announced
that the Company will participate in the following investor
conferences:
- Evercore 7th Annual HealthCONx Conference: Fireside chat on
Tuesday, December 3, 2024, at
3:50 p.m. ET
- Piper Sandler 36th Annual Healthcare Conference:
Presentation on Wednesday, December 4,
2024, at 11:10 a.m. ET
The live events and replays of the presentations will be
available under "Events and Presentations" through the investor
relations section of the Company's website
at https://ir.regulusrx.com/events and archived for 90 days
following the presentation date.
About Regulus
Regulus Therapeutics Inc. (Nasdaq: RGLS)
is a biopharmaceutical company focused on the discovery and
development of innovative medicines targeting microRNAs. Regulus
has leveraged its oligonucleotide drug discovery and development
expertise to develop a pipeline complemented by a rich intellectual
property estate in the microRNA field. Regulus maintains its
corporate headquarters in San Diego,
CA.
Forward-Looking Statements
Statements contained in
this press release regarding matters that are not historical facts
are "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
associated with the Company's RGLS8429 program and preclinical
pipeline, the potential that RGLS8429 may be eligible for an
Accelerated Approval pathway, potentially achieving therapeutic
efficacy and clinical translation for patients, the expected timing
for reporting interim or topline data, and the timing and future
occurrence of other preclinical and clinical activities. Because
such statements are subject to risks and uncertainties, actual
results may differ materially from those expressed or implied by
such forward-looking statements. Words such as "believes,"
"anticipates," "plans," "expects," "intends," "will," "goal,"
"potential" and similar expressions are intended to identify
forward-looking statements. These forward-looking statements are
based upon Regulus' current expectations and involve assumptions
that may never materialize or may prove to be incorrect. Actual
results and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of
various risks and uncertainties, which include, without limitation,
the risk that the approach we are taking to discover and develop
drugs is novel and may never lead to marketable products, that
preliminary or topline results are based on a preliminary analysis
of key efficacy and safety data, and such data may change following
a more comprehensive review of the data related to the clinical
trial and may not be indicative of future results, the FDA has not
designated RGLS8429 for an Accelerated Approval pathway and such
designation may not lead to a faster development, regulatory review
or approval process and does not increase the likelihood that
RGLS8429 will receive marketing approval, the risk that preclinical
and clinical studies may not be successful, risks related to
regulatory review and approval, risks related to our reliance on
third-party collaborators and other third parties, risks related to
intellectual property, risks associated with the process of
discovering, developing and commercializing drugs that are safe and
effective for use as human therapeutics, the risk that additional
toxicology data may be negative, and risks related to our ability
to successfully secure and deploy capital. These and other risks
are described in additional detail in Regulus' filings with the
Securities and Exchange Commission, including under the "Risk
Factors" heading of Regulus' quarterly report on Form 10-Q
available on the Company's website or at www.sec.gov. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Regulus undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regulus-therapeutics-announces-participation-at-upcoming-healthcare-investment-conferences-302315853.html
SOURCE Regulus Therapeutics Inc.